Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study.
The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia. It focuses on an analysis of a sub-group of 20 patients receiving treatment of the donepezil in an extended Czech double-blind placebo controlled study.
Pérez
M
M
Department of Psychiatry, Hospital Havirov, Charles University, Prague, Faculty of Medicine, Hradec Kralove, Czech Republic. prim.psychiatrie@nsphav.cz
Tůma
I
I
Pytela
O
O
Kadlecová
E
E
Zemanová
M
M
Lenderová
Z
Z
D000293:Adolescent; D000328:Adult; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D018153:Czech Republic; D000077265:Donepezil; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D009483:Neuropsychological Tests; D010880:Piperidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil